1. Why would illegal marketing activities feature so frequently in the pharmaceutical industry? At what point would they be considered endemic?
2. Why would pharmaceutical companies choose to continue such practices even when it is made clear that they are illegal?
3. What should the respective boards of directors be doing here? How should they be held accountable?
4. Critics argue that fines are too affordable. In other words, a $1 billion fine for activities that generate several billion dollars in illegal sales simply becomes a cost of doing business. Should fines be more punitive? How much would be enough?
5. Is the payment of a monetary fine sufficient restitution for these offences? Why or why not?
6. How could this apparently endemic problem be approached differently?